# US 10,869,869 B2 · Method of adjuvant cancer treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,869,869 B2
- Document ID: US10869869B2
- Status: Granted
- Kind: B2
- Application number: 16/664,978
- Filed: 2019-10-28
- Published: 2020-02-20
- Granted: 2020-12-22
- Earliest claimed: 2012-09-04
- Assignees: Novartis AG
- Applicants: Novartis AG
- Inventors: Sylvie Laquerre; Peter F. Lebowitz
- Web page: https://patentgrep.com/patent/US10869869B2

## CPC

- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61P 17/00: Drugs for dermatological disorders
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a method of providing adjuvant treatment to a human patient which comprises administering to such a patient therapeutically effective doses of dabrafenib and trametinib for a time period sufficient to increase relapse-free survival (RFS).

## Claims

### Claim 1

A method for providing adjuvant treatment to a patient with a prior diagnosis of melanoma which has been resected, comprising the steps of:
a) administering to said patient therapeutically effective doses of dabrafenib and trametinib, wherein said dabrafenib is administered at an amount of 150 mg twice a day and said trametinib is administered at an amount of 2 mg once daily; and
b) increasing relapse-free (RFS) of said patient after resection of said melanoma.

### Claim 2 (depends on 1)

The method of claim 1, wherein said patient has a prior diagnosis of stage III melanoma, which has been resected.

### Claim 3 (depends on 1)

The method of claim 1, wherein said patient has a prior diagnosis of BRAF V600 mutation-positive melanoma, which has been resected.